Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Wykorzystanie narzędzia przesiewowego do opisania obciążenia rakiem związanego z HIV i charakterystyki pacjentów w AMC

21 października 2026 zaktualizowane przez: AIDS Malignancy Consortium

Wykorzystanie narzędzia przesiewowego do opisania obciążenia rakiem związanego z HIV i charakterystyki pacjentów w konsorcjum zajmującym się zwalczaniem złośliwości AIDS Próba konsorcjum zajmującego się zwalczaniem złośliwości AIDS (AMC)

This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in cancer clinical trials. Optional quality of life surveys will be used to learn more about how HIV and cancer and HIV and cancer treatment affect people.

Przegląd badań

Szczegółowy opis

Primary Objective: To estimate the number of cancers in people with HIV (PWH) who present for care at domestic AMC sites

Secondary Objectives: To characterize participants that are eligible but not enrolled onto AMC clinical trials to understand site-specific and trial-specific accrual barriers

Exploratory Objectives: 1. To standardize and expand the quantity and quality of sociodemographic and cancer diagnostic and treatment characteristics collected for PWH receiving care at domestic AMC sites. 2. To describe cancer patient health-related QOL for PWH at domestic AMC sites using validated tools: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30] and Supportive Care Needs Survey Short Form 34 [SCNS-SF34]

Outline: Participants identified via screening of electronic medical records or institutional databases. All eligible participants attend one visit for the collection of broad demographic and clinical data. Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit. Data collection at study visits will occur via survey procedures and/or medical record review.

Typ studiów

Obserwacyjny

Zapisy (Rzeczywisty)

460

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • San Juan, Portoryko, 00921
        • University of Puerto Rico
    • California
      • La Jolla, California, Stany Zjednoczone, 92903
        • Moores UCSD Cancer Center
    • District of Columbia
      • Washington D.C., District of Columbia, Stany Zjednoczone, 20037
        • George Washington University Cancer Center
    • Florida
      • Miami, Florida, Stany Zjednoczone, 33136
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Tampa, Florida, Stany Zjednoczone, 33612
        • Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60612
        • University of Illinois at Chicago
    • Maryland
      • Baltimore, Maryland, Stany Zjednoczone, 21231
        • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    • Missouri
      • St Louis, Missouri, Stany Zjednoczone, 63110
        • Washington University School of Medicine
    • New York
      • New York, New York, Stany Zjednoczone, 10029
        • Mount Sinai Hospital
      • New York, New York, Stany Zjednoczone, 10010
        • Weill Cornell Medicine - Cornell Clinical Trials Unit
      • The Bronx, New York, Stany Zjednoczone, 10467
        • Montefiore Medical Center
    • Ohio
      • Columbus, Ohio, Stany Zjednoczone, 43210
        • The Ohio State University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stany Zjednoczone, 19106
        • Abramson Cancer Center at Pennsylvania Hospital
    • Texas
      • Houston, Texas, Stany Zjednoczone, 77030
        • MD Anderson Cancer Center
    • Utah
      • Salt Lake City, Utah, Stany Zjednoczone, 84112
        • Huntsman Cancer Institute - University of Utah
    • Washington
      • Seattle, Washington, Stany Zjednoczone, 98101
        • Virginia Mason Medical Center

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

Participants with a dual diagnosis of both cancer (current or diagnosed within 5 years) and underlying HIV infection, who present for care at AMC domestic sites.

Opis

Inclusion Criteria:

  • Participant can understand and is willing to sign a written informed consent document.

  • HIV positive. Documentation of HIV-1 infection by means of any one of the following:

    • Documentation of an HIV diagnosis in the medical record by a licensed health care provider;
    • Documentation of receipt of antiretroviral therapy (ART) (i.e., at least two different medications that do not constitute a prescription for pre-exposure prophylaxis [PrEP]) by a licensed health care provider. Documentation may be a record of an ART prescription in the medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name;
    • HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating >1000 RNA copies/mL;
    • Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay.

Note: The term "licensed" refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally (e.g., U.S. FDA).

WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay, or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), a Western blot, or a plasma HIV-1 RNA viral load.

  • Patient was diagnosed with or treated for cancer within the last 5 years. Participants will qualify under one of three categories:

    • New, primary or recurrent diagnosis -Considering or currently receiving cancer treatment
    • Metastatic or locally advanced cancer - This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies.
    • Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy.
  • Age ≥ 18 years.

  • Participant presents to an AMC domestic clinical trial site for either clinical care or research.

Exclusion Criteria:

  • Participants who do not fulfill the criteria as listed above are ineligible.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: COHORT
  • Perspektywy czasowe: PROSPECTIVE

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
New, primary or recurrent disease

Considering or currently receiving cancer treatment

Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.

Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.

Metastic or locally advanced cancer

This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies.

Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.

Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.

Prior cancer

Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy.

Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Number of Cancers in People With HIV (PWH) Who Present for Care at Domestic AMC Sites
Ramy czasowe: Enrollment

For each cancer group listed below, the number of new and existing cases per month will be estimated. The distribution of cancer types will be computed as percentages and compared to the cancer type distribution in the HIV/AIDS Cancer Match (HACM) Study:

  1. Solid organ tumors associated with human papillomavirus (HPV) infection
  2. Solid organ tumors unrelated to HPV
  3. Kaposi sarcoma
  4. Hematologic malignancies
Enrollment

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants Eligible for AMC Trials Who Are Successfully Enrolled
Ramy czasowe: Baseline

This will be calculated by the number of participants enrolled who meet site-based AMC trial eligibility compared to the number of eligible participants at each site who meet site-based AMC trial eligibility.

Baseline

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Describe the Cancer Diagnostics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
Ramy czasowe: Baseline

The distribution of participant cancer diagnosis variable will be summarized.

Baseline
Describe the Gender Distribution of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
Ramy czasowe: Baseline

The distribution of participant gender variable will be summarized.

Baseline
Describe the Age Distribution of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
Ramy czasowe: Baseline and 12 weeks

The distribution of participant characteristics will be summarized. Continuous variables [e.g. age, height, weight] will be summarized as mean (std) if they are normally distributed, otherwise they will be summarized as median (IQR). Categorical variables [e.g. tobacco use, ART medications, comorbidities] will be summarized as frequency (%).

Baseline and 12 weeks
Describe the Treatment Characteristics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
Ramy czasowe: Baseline

The distribution of participant cancer treatment at enrollment will be summarized.

Baseline
Planned Cancer Therapy for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment
Ramy czasowe: 12 weeks

The frequency of planned cancer treatment regimens (at baseline) successfully initiated will be summarized.

12 weeks
Describe the Health-related QOL of Cancer Patients With HIV at Domestic AMC Sites Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]
Ramy czasowe: Baseline

EORTC QLQ-C30 subscale and overall scores will be used to describe participant symptom and health-related quality of life burden. Baseline EORTC QLQ-C30 scores will be compared according to cancer group. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and single items assessing additional symptoms and perceived financial impact of the disease. Most questions use a 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions use a 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.

Baseline
Describe the Supportive Care Needs of Cancer Patients With HIV at Domestic AMC Sites Using Supportive Care Needs Survey Short Form 34 [SCNS-SF34]
Ramy czasowe: Baseline

Supportive Care Needs Survey Short Form 34 [SCNS-SF34] scores will be used to categorize participants based on the degree to which their needs are met. Baseline SCNS-SF34 scores will be compared according to cancer group. The SCNS-SF34 is a 34-item questionnaire measuring the supportive care need and level of need for people diagnosed with cancer in the last month. It incorporates the underlying domains: physical and daily living, psychological, sexuality and health system, information and patient support. All the questions use 5-point scale (1 'Not applicable' to 5 'High need); with a higher score indicating a higher level of need.

Baseline
Change of Quality of Life at 12 Weeks From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]
Ramy czasowe: Baseline and 12 weeks

EORTC QLQ-C30 will be summarized, both overall and at the ~12-week follow-up, according to participant characteristics and cancer groups. Overall change in QOL will be compared with paired tests and change according to groups will be compared using t-tests, ANOVA, or nonparametric tests. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role,cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms and perceived financial impact of the disease. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.

Baseline and 12 weeks
Change of Needs From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using Supportive Care Needs Short Survey Form 34 [SCNS-SF34]
Ramy czasowe: Baseline and 12 weeks

Supportive Care Needs Short Survey Form 34 [SCNS-SF34] scores will be summarized, both overall and at the ~12-week follow-up, according to participant characteristics and cancer groups. Overall change in scores will be compared with paired tests and change according to groups will be compared using t-tests, ANOVA, or nonparametric tests. The SCNS-SF34 is a 34-item questionnaire measuring the supportive care need and level of need for people diagnosed with cancer in the last month. It incorporates the underlying domains: physical and daily living, psychological, sexuality and health system, information and patient support. All the questions use 5-point scale (1 'Not applicable' to 5 'High need). Scores are averaged, and transformed to 0-100 scale;, with a higher score indicating a higher level of need.

Baseline and 12 weeks

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Krzesło do nauki: Anna E Coghill, PhD, MPH, AIDS Malignancy Consortium

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

25 lipca 2023

Zakończenie podstawowe (Rzeczywisty)

28 lutego 2025

Ukończenie studiów (Rzeczywisty)

2 czerwca 2025

Daty rejestracji na studia

Pierwszy przesłany

1 sierpnia 2022

Pierwszy przesłany, który spełnia kryteria kontroli jakości

18 sierpnia 2022

Pierwszy wysłany (Rzeczywisty)

22 sierpnia 2022

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

5 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

21 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • AMC-115
  • UM1CA121947 (Grant/umowa NIH USA)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj